Biotechnology
11 November 2025 Partnering with AI vendors can open doors for startups and small companies but it also brings serious risks. Experts at AI & IP Europe share key lessons on contracts, data ownership, ring-fencing, monitoring, and exit planning, as Marisa Woutersen reports.
11 November 2025
31 October 2025
27 October 2025
Latest Features
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Africa
Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization.
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis.
More News
24 October 2025 A panel of experts at LSPN shared how AI is forcing companies to rethink everything from obviousness arguments to the choice between patents and trade secrets, and why the claims filed today may be invalid tomorrow.
23 October 2025 Experts at LSPN North America Fall explore the often-overlooked factors that can make or break transactions, from employee retention strategies to cross-border patent standards.
22 October 2025 The Supreme Court’s 2023 Amgen ruling turned patent strategy upside down. Now lawyers are rethinking everything they thought they knew about protecting inventions. Marisa Woutersen reports from LSPN North America–Fall.
22 October 2025 Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.
9 October 2025 The promises and pitfalls of AI took centre stage at CIPA’s annual congress in Bristol this week, as Sarah Speight reports.
7 October 2025 The pharma giant will share rights to new innovations with an AI-driven organoid platform designed to produce fully human antibodies in weeks.
2 October 2025 From stalled drug approvals to suspended patent investigations, US rightsholders face mounting uncertainty during the federal freeze.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox